HIND
Vyome Holdings, Inc.
There isn't enough reported data to score HIND yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
HIND Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
HIND's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
HIND PE Valuation
HIND has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
HIND Forward outlook
There aren't enough analyst estimates for HIND to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
HIND Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$226,722.00 | +$953,578.00 |
| Q2 2023 | -$371,606.00 | +$1,087,094.00 |
| Q1 2023 | -$510,342.00 | +$939,658.00 |
| Q4 2022 | -$628,894.00 | +$1,076,306.00 |
| Q3 2022 | -$1,180,300.00 | -$84,100.00 |
| Q2 2022 | -$1,458,700.00 | -$617,700.00 |
| Q1 2022 | -$1,450,000.00 | -$275,500.00 |
| Q4 2021 | -$1,705,200.00 | -$321,900.00 |
UNH has the stronger earnings trend. Trailing diluted EPS is down 100% for HIND versus UNH down 8.5%.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
HIND Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $58K | +67% |
| Q2 2026 | $27K | -98% |
| Q1 2026 | $31.6K | -97% |
| Q4 2025 | $36.6K | -98% |
| Q3 2025 | $34.6K | -98% |
| Q2 2025 | $1.2M | -37% |
| Q1 2025 | $1.1M | -43% |
| Q4 2024 | $1.8M | -8.9% |
HIND's revenue is recovering but still below its 2021 peak: $57,998 last quarter, up 67% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1761% | +23001 points |
| Q2 2026 | -3200% | -2978 points |
| Q1 2026 | -3577% | -3379 points |
| Q4 2025 | -3707% | -3613 points |
| Q3 2025 | -24762% | -24685 points |
| Q2 2025 | -222% | -118 points |
| Q1 2025 | -198% | -85 points |
| Q4 2024 | -94% | +1.3 points |
HIND's operating margin was −1761% last quarter, up 23001 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over HIND on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over HIND on profitability, with a higher operating margin.
HIND Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$627.6K | -114% |
| Q2 2026 | -$903.7K | +$3.6M |
| Q1 2026 | -$1.4M | +$683K |
| Q4 2023 | -$2.5M | +$452K |
| Q3 2023 | -$2.8M | +$2.5M |
| Q2 2023 | -$6.7M | -$264K |
| Q1 2023 | -$5.1M | +$2.3M |
| Q4 2022 | -$2.9M | +$584K |
HIND has burned cash in almost every quarter: −$4M over the past year, against −$5M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over HIND on cash generation, producing positive trailing cash flow while its opponent burns cash.
HIND Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +67 shares |
| 1 year | +767% | +4.6K shares |
| 3 years | +18314% | +5.1K shares |
HIND has 5,156 diluted shares, up 767% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over HIND on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
HIND Net Leverage
HIND's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
HIND Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.9 | Oversold |
| Stochastic | 12.6 | Oversold |
HIND's weekly RSI is 28 (oversold) and its Stochastic is 13 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
HIND PE vs Healthcare Sector
HIND has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
HIND Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.84 | 11% below |
| 20 week MA | $2.04 | 20% below |
| 50 week MA | $2.43 | 33% below |
| 100 week MA | $47.1 | 97% below |
| 200 week MA | $3,472.6 | 100% below |
HIND is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over HIND on trend strength, trading above more of its moving averages.
HIND Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,644,300.0 | $1,383,300.0 | -16% |
| 2021 | $1,383,300.0 | $574,200.0 | -58% |
| 2022 | $574,200.0 | $35,612.0 | -94% |
| 2023 | $35,612.0 | $1,450.0 | -96% |
| 2024 | $1,450.0 | $455.0 | -69% |
| 2025 | $455.0 | $3.73 | -99% |
| 2026 YTD | $3.73 | $1.63 | -56% |
HIND has finished every year since 2020 lower, and it's down 56% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over HIND on returns for 2026, with the stronger performance.